A CNS-Penetrant BTK Inhibitor Modulates Multiple Pathogenic Pathways Implicated in Multiple Sclerosis

A CNS-Penetrant BTK Inhibitor Modulates Multiple Pathogenic Pathways Implicated in Multiple Sclerosis

ACTRIMS – Feb 2023

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study